Of the 46 18F-FLT PET/CT scans, 43 (93%) were performed on a Siemens Biograph 64 TruePoint PET/CT scanner and 3 (7%) on a Siemens Emotion Duo PET/CT scanner approximately 1 h after a median injected activity of 247.9 MBq (IQR, 229.4–255.3 MBq). Intravenous and oral contrast media were administered in 33 scans (72%) and 36 scans (78%), respectively.
Several SUV parameters were assessed on PET 1 and PET2: SUVmax, SUVpeak, SUVmean, and SUV for total-lesion FLT with a 40%, 50%, 60%, and 80% cutoff of SUVmax. Because SUVmax proved to be equal or superior to the other PET parameters, we selected SUVmax for further analyses. 18F-FLT PET/CT images were interpreted by 1 reader. The reader was aware of the sarcoma diagnosis but not of the treatment regimen or other clinical and outcome data.
Posttreatment pathology specimens were assessed by tumor necrosis or fibrosis and by Ki-67 and TK1 expression as described previously (8 (link)).
Several SUV parameters were assessed on PET 1 and PET2: SUVmax, SUVpeak, SUVmean, and SUV for total-lesion FLT with a 40%, 50%, 60%, and 80% cutoff of SUVmax. Because SUVmax proved to be equal or superior to the other PET parameters, we selected SUVmax for further analyses. 18F-FLT PET/CT images were interpreted by 1 reader. The reader was aware of the sarcoma diagnosis but not of the treatment regimen or other clinical and outcome data.
Posttreatment pathology specimens were assessed by tumor necrosis or fibrosis and by Ki-67 and TK1 expression as described previously (8 (link)).
Free full text: Click here
